Related Experiment Video
Updated: Jun 24, 2026
08:41
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
Molecular mechanisms involved in NAFLD progression
Mariano Malaguarnera1, Michelino Di Rosa, Ferdinando Nicoletti
1Department of Internal Medicine, University of Catania, Catania, Italy.
Journal of Molecular Medicine (Berlin, Germany)
|April 9, 2009
Summary
Non-alcoholic fatty liver disease (NAFLD) involves liver fat buildup, potentially progressing to non-alcoholic steatohepatitis (NASH). This review explores molecular mediators driving NASH progression for earlier diagnosis and targeted treatments.
Area of Science:
- Hepatology
- Metabolic Disorders
- Molecular Biology
Background:
- Non-alcoholic fatty liver disease (NAFLD) is a growing metabolic disorder characterized by liver fat accumulation.
- NAFLD spectrum ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), a condition linked to insulin resistance and metabolic syndrome.
- Progression to end-stage liver disease involves complex interactions of nutritional, lifestyle, and genetic factors.
Purpose of the Study:
- To review and assess molecular mediators involved in initiating and progressing NASH.
- To identify potential targets for earlier diagnosis and more specific treatments for NASH.
Main Methods:
- Literature review and analysis of existing studies on NAFLD and NASH.
- Focus on molecular mechanisms underlying disease progression.
- Synthesis of current knowledge on molecular mediators.
Main Results:
- Insulin resistance is a key factor in NAFLD progression.
- Multifactorial interactions contribute to hepatocellular damage, inflammation, and fibrosis in NASH.
- Molecular mechanisms driving NASH progression are not fully characterized.
Conclusions:
- Understanding molecular mediators is crucial for advancing NASH diagnosis and treatment.
- Further research into molecular pathways can lead to targeted therapeutic strategies.
- Early diagnosis and specific treatments are needed for effective NASH management.
Related Concept Videos
01:38Inflammation
Overview
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:21Chronic Pancreatitis II: Pathophysiology
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...